{content}

Study list

ECRAID-PRIME

Belgium France Germany Ireland Poland Spain United Kingdom Georgia
|
2024
  • Adults
  • Community
  • Primary care
  • SARS-CoV-2
  • Influenza virus
  • Influenza A(H5N1) virus
  • Acute SARS-CoV-2
  • Avian Influenza
  • Influenza
  • Pharmacological intervention
  • Nitric Oxide Nasal Spray

Fuensalida Novo

Spain
|
2024-2026
  • General population
  • Elderly
  • Adult
  • Community
  • SARS-CoV-2
  • Post-COVID-19
  • Non pharmacological intervention
  • Rehabilitation
  • Stimulation

Long-termAPP

France
|
2024-2025
  • Adults
  • General population
  • Elderly
  • Hospital wide
  • Intensive care unit
  • SARS-CoV-2
  • Post-COVID-19

HINT

Germany
|
2024-2025
  • Adults
  • General population
  • Elderly
  • Community
  • SARS-CoV-2
  • Post-COVID-19

MASH-1

United Kingdom France Spain Poland
|
2024-2024
  • Adults
  • Fragile population
  • Immunocompromised host
  • People at high risk of STIs
  • People living with HIV
  • PrEP users
  • Outpatient clinic
  • Non-hospital health centre
  • STD/STI clinic
  • Monkeypox virus
  • Monkeypox virus infection

Rizzardini

Italy
|
2024-2024
  • Adults
  • General population
  • Hospital wide
  • Outpatient clinic
  • Monkeypox virus
  • Monkeypox virus infection

POSTCOVID

Poland
|
2023-2028
  • Adults
  • General population
  • Elderly
  • SARS-CoV-2
  • Post-COVID-19
  • Pharmacological intervention
  • Pregabalin

Eddy

United Kingdom
|
2023-2024
  • Adults
  • General population
  • Outpatient clinic
  • SARS-CoV-2
  • Post-COVID-19
  • Non pharmacological intervention
  • Rehabilitation

Franke

Germany
|
2023-2025
  • Adults
  • General population
  • Elderly
  • SARS-CoV-2
  • Post-COVID-19
  • Pharmacological intervention
  • Corticosteroid
  • Methylprednisolone

Prüßler

Germany
|
2023-2025
  • Adults
  • General population
  • Elderly
  • Outpatient clinic
  • SARS-CoV-2
  • Post-COVID-19
  • Non pharmacological intervention
  • Immunoadsorption

NOVELLA

Russian Federation
|
2023-2024
  • Adults
  • Elderly
  • Fragile population
  • Immunocompromised host
  • SARS-CoV-2
  • Post-COVID-19
  • Pharmacological intervention
  • Monoclonal antibodies
  • AZD3152

LCHydroxy

United Kingdom
|
2023-2024
  • Adults
  • General population
  • Elderly
  • Primary care
  • SARS-CoV-2
  • Post-COVID-19
  • Non pharmacological intervention
  • Hydroxy gas